PR Newswire
prLean Left
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKEtranslating…
Repatha is the First and Only PCSK9 Inhibitor Shown to Lower the Risk of Dying from All Causes, Including Cardiovascular Events, in High-Risk Primary Prevention Patients in a Phase 3 Trial Separate Global Real-World Analyses Show Persistent Gaps in Lipid Management, With Many…
Keywords#RISK#PATIENTS#REPATHA#A FIRST#A FIRST HEART